Myasthenia Gravis

Latest News

osteoporosis | Image Credit: reineg-stock.adob.ecom
Combining Bone Health, Function Scores Refines MG Fracture Prediction

May 30th 2025

Combining FRAX and MG-ADL assessments enhances fracture risk prediction in patients with myasthenia gravis (MG), guiding targeted interventions for better outcomes.

Light sensitivity is a potential symptom of myasthenia gravis that has historically been under-researched, according to study authors. | Image credit: lexiconimages - stock.adobe.com
Light Sensitivity Linked With Lower Quality of Life in Myasthenia Gravis

May 23rd 2025

Rystiggo | Image Credit: © UCB
Rozanolixizumab for gMG Approved in Japan for Self-Administration

May 15th 2025

FDA approved. | Image Credit: Pawel - stock.adobe.com
FDA Approves Nipocalimab for Generalized Myasthenia Gravis

April 30th 2025

Myasthenia gravis | Image Credit: © missbobbit-stock.adobe.com
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod

April 18th 2025

More News

term myasthenia gravis | Image Credit: lexiconimages - stock.adobe.com
April 11th 2024

Bioinformatics, Machine Learning Reveal New Insights Into MG-Associated DCM

AJMC Contributor
Researchers explain that these insights have important implications, if validated in further research, as challenges with early detection of dilated cardiomyopathy complicate myasthenia gravis (MG)-prognosis.
Myasthenia gravis | Image Credit: Andrii - stock.adobe.com
April 6th 2024

Online Discussions Illuminate Daily Challenges, Treatment Hurdles in MG

AJMC Contributor
Analyzing trends from online conversations among patients with myasthenia gravis (MG), researchers found that issues with current treatments were mentioned in nearly 24% of conversations.
myasthenia gravis | Image Credit: luchschenF - stock.adobe.com
March 28th 2024

Patients With Autoimmune Thyroid Disease at Higher Risk of Myasthenia Gravis

AJMC Contributor
These insights, explain the researchers of the study, complement observational studies, which have previously indicated a causal relationship between the 2 diseases.
Myasthenia Gravis with phrase on the page | Image Credit: Yurii Kibalnik - stock.adobe.com
March 23rd 2024

Researchers Highlight Current Gaps in Research on Exercise Use in MG

AJMC Contributor
The researchers note that their findings can help inform adjustments for future research among individuals living with myasthenia gravis (MG).
Myasthenia gravis stock image | Image Credit: lhphotos - stock.adobe.com
March 21st 2024

Pilot Study Links Possible Lab Markers With Risk of Myasthenic Crisis

AJMC Contributor
These findings, together with real-world data, could help inform risk classification of myasthenic crisis beyond known risk factors, such as infection.
Older man and doctor on telehealth visit | Image Credit: fizkes - stock.adobe.com
March 13th 2024

Rising Myasthenia Gravis Rates in Older US Men Spark Research, Public Health Concerns

Gwen Mergian
Incidence and prevalence of myasthenia gravis in the US has increased surprisingly since last examined more than 20 years ago.
Concept of Myasthenia Gravis writing on sticky notes isolated on Wooden Table | Image credit: syahrir - stock.adobe.com
March 8th 2024

Review: Vigilance Warranted to Prevent, Treat Transient Neonatal Myasthenia Gravis

Jared Kaltwasser
Preventive measures can reduce the risk to newborns, but careful monitoring is necessary, the authors said.
Conceptual photo about Myasthenia Gravis | Image credit: Yurii Kibalnik-stock.adobe.com.jpeg
March 5th 2024

Batoclimab Outperforms Placebo in Phase 3 Generalized MG Trial

Jared Kaltwasser
The fully humanized monoclonal antibody led to results among patients with generalized myasthenia gravis (MG) similar to that of efgartigimod, the authors said.
Gut microbiome - sdecoret - stock.adobe.com
February 29th 2024

Analysis Identifies Gut Microbiota Affecting Risk of MG

AJMC Contributor
The Mendelian randomization–based analysis, which examines how variation in genes have a causal effect of an exposure on certain outcomes, identified 12 gut microbiota associated with either an increased of or protective effect against MG.
Graphical representation of autoantibody diseases | Image credit: lexiconimages - stock.adobe.com
February 29th 2024

Intravenous Nipocalimab Infusions Safe, Effective Against Autoantibody-Mediated Diseases

Luke Halpern
After being found effective over longer durations with smaller doses, this study found that nipocalimab infusions resulted in a tolerable safety profile and remained effective even in shorter treatment periods and with larger doses.
Myasthenia gravis | Image credit: Andrii - stock.adobe.com
February 22nd 2024

Phase 2 Results Show Safety, Dose-Dependent Improvements in Function With Nipocalimab in gMG

AJMC Contributor
Based on data from the study, a phase 3 confirmatory trial is underway for the humanized monoclonal antibody.
Myasthenia gravis report | Image credit: mdaros - stock.adobe.com
February 15th 2024

Vyvgart Phase 3 Extension Study Data Affirm Long-Term Safety, Efficacy in gMG

AJMC Staff
Details from the final interim data analysis of the ADAPT+ study confirm previous findings seen with efgartigimod (Vyvgart) in generalized myasthenia gravis (gMG), the rare neuromuscular autoimmune disease.
MYASTHENIA GRAVIS inscription on the black board Image credit: Yurii Kibalnik - stock.adobe.com
February 9th 2024

Phase 3 Trial Will Assess Whether Humanized mAb Addresses Patient Needs in MG

AJMC Staff
Dubbed the FLEX trial, the study will explore whether batoclimab will address important patient needs throughout different phases of the myasthenia gravis (MG).
Myasthenia Gravis illustration isolated on red background | Image credit: lhphotos - stock.adobe.com
February 6th 2024

Possible Increase in Prevalence of Alzheimer Disease Found in Patients With Myasthenia Gravis

Luke Halpern
Investigators observed an increase in the prevalence of Alzheimer disease in patients with diagnosed myasthenia gravis (MG), which indicates that MG is an independent risk factor for AD.
Myasthenia gravis | Image credit: lexiconimages - stock.adobe.com
January 31st 2024

IV Methylprednisolone, Tacrolimus Effective in Prednisone-Resistant Ocular MG

AJMC Staff
Researchers have retrospectively analyzed data from nearly 60 patients with ocular myasthenia gravis (MG) not adequately responding to oral prednisone, finding that both intravenous (IV) methylprednisolone and tacrolimus monotherapy helped reduce symptoms.
Old man with eye fatigue | Image Credit: sebra - stock.adobe.com
January 30th 2024

Overlapping Symptoms Challenge Diagnosis in Rare Co-Occurrence of PD, MG

Gwen Mergian
Since 1987, only 57 cases of comorbid Parkinson disease (PD) and myasthenia gravis (MG) have been reported.
Diagnosis: Myasthenia Gravis | Image Credit: © Николай Зотов - stock.adobe.com
January 27th 2024

New MG Research Focuses on More Tailored Treatment, Bibliometric Analysis Finds

AJMC Staff
The data search of Web of Science Core Collection, spanning 2003 to 2022, identified various prospective directions in myasthenia gravis (MG) research, including in personalized treatment, subtype-based treatment, and novel immunotherapeutic strategies.
Myasthenia gravis | Image credit: Andrii - stock.adobe.com
January 25th 2024

Claims Data Suggest High Clinical, Economic Burden of MG Exacerbations Despite Treatment Options

AJMC Staff
The data suggest this burden among patients who have myasthenia gravis (MG) is prevalent across insurance types.
Faceless male patient speaking with doctor holding a clipboard | DragonImages - adobe.stock.com
January 19th 2024

New Therapies More Precisely Treat Myasthenia Gravis

Laura Joszt, MA
Once treated with a one-size-fits-all approach, changes in the landscape for myasthenia gravis are allowing for more precise treatment of the disease.
Notes on myasthenia gravis | Image Credit: syahrir - stock.adobe.com
December 29th 2023

Low-Dose Rituximab Effective Against MuSK-Positive MG in New Analysis

Maggie L. Shaw
Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.
Graphic representing the top 5 myasthenia gravis articles of 2023
December 18th 2023

Top 5 Most-Read Myasthenia Gravis Articles of 2023

Maggie L. Shaw
In our coverage of myasthenia gravis this year, the top developments show the effects of COVID-19 continue to be uncovered, a new FDA approval for generalized disease, and assessing patient outcomes following uncontrolled disease and respiratory distress.
Myasthenia gravis blood test | Image credit: luchschenF - stocka.adobe.com
December 15th 2023

New Data on Batoclimab for MG Indicate Effective Treatment Potential

Maggie L. Shaw
Two doses of batoclimab were evaluated for their effectiveness in patients with generalized myasthenia gravis (MG) who were seropositive.
Myasthenia gravis diagnosis | Image Credit: Andrii - stock.adobe.com
December 6th 2023

Myasthenia Gravis Trial Set for CAR T CABA-201

Noah Stansfield
The chimeric antigen receptor T-cell therapy (CAR T) from Cabaletta Bio has already been cleared for trials in systemic lupus erythematosus, myositis, and systemic sclerosis.
The words "Diagnosis: Myasthenia Gravis" on a notebook with a stethoscope and pills | Image Credit: Николай Зотов stock.adobe.com
December 3rd 2023

New Data Update Myasthenia Gravis Outcomes for Patients in Australia

Maggie L. Shaw
Patients living with myasthenia gravis in Australia were surveyed their demographic information, clinical features of the autoimmune disease, adverse effects from treatment, and quality of life. Outcomes were compared against 2011 data from Australia and 2019 data from the United States.
Patient-Specific Therapy Model | image credit: vrx123 - stock.adobe.com
December 1st 2023

Patient-Specific Targeted Therapies Could Mitigate Immune-Related Adverse Events

Kyle Munz
A case report highlights the benefits of applying patient-tailored therapies to mitigate the effects of neuromuscular immune-related adverse events and improve patient outcomes.
Medical research, phases of clinical trials | Image Credit: Olivier Le Moal - stock.adobe.com
November 24th 2023

Kyverna’s CAR T-Cell Therapy Expands Autoimmune Investigations Into Myasthenia Gravis

Victoria Johnson
The therapy is already being evaluated in patients with lupus nephritis and diffuse cutaneous systemic sclerosis.
Woman using digital x-ray of human intestine holographic scan projection 3D rendering | Image Credit: sdecoret - stock.adobe.com
November 14th 2023

Investigators Explore Potential Link Between the Gut Microbiome and Myasthenia Gravis Risk

Maggie L. Shaw
This new study sought to solidify a relationship between certain microbes in intestinal flora and the risk of developing myasthenia gravis, specifically those potentially reducing that risk.
Glenn Phillips, PhD | Image Credit: Argenx
November 11th 2023

Racial Disparities in Acute Care Utilization Seen Among Patients With Myasthenia Gravis

Isabella Ciccone, MPH
Research presented at the 2023 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting emphasizes the potential need for patient support programs targeting at-risk populations to enhance disease management and reduce acute care utilization in myasthenia gravis.
Medical concept meaning MYASTHENIA GRAVIS with inscription on the sheet | Image Credit: Yurii Kibalnik - stock.adobe.com
November 8th 2023

Myasthenia Gravis Potential Result of Cancer Treatment

Maggie L. Shaw
When patients are undergoing treatment for cancer, clinicians should be aware of the potential to develop myasthenia gravis from immune checkpoint inhibitors (ICI), new research stresses, with ongoing surveillance and risk factor identification becoming necessary steps.
Judith Thompson, PharmD, MPH | Image Credit: UCB Pharma
November 3rd 2023

SDOH Lead to Greater Suboptimal Treatment Response in Myasthenia Gravis

Marco Meglio
A retrospective study presented at the 2023 American Association of Neuromuscular and Electrodiagnotsic Medicine meeting revealed that social determinants of health (SDOH) are linked to poorer treatment outcomes in patients who have myasthenia gravis, emphasizing the need for identifying and supporting at-risk individuals.
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo